Pro-Dex Inc (NASDAQ:PDEX) Short Interest Update

Pro-Dex Inc (NASDAQ:PDEX) saw a significant decline in short interest during the month of November. As of November 29th, there was short interest totalling 5,200 shares, a decline of 11.9% from the November 14th total of 5,900 shares. Based on an average daily trading volume, of 15,600 shares, the days-to-cover ratio is presently 0.3 days. Approximately 0.2% of the shares of the company are sold short.

Shares of PDEX stock traded down $0.09 during trading hours on Friday, reaching $15.64. 7,889 shares of the company’s stock were exchanged, compared to its average volume of 21,072. Pro-Dex has a fifty-two week low of $10.37 and a fifty-two week high of $17.95. The stock has a market capitalization of $62.49 million, a P/E ratio of 16.91 and a beta of 1.50. The business has a fifty day moving average price of $13.67 and a 200-day moving average price of $13.67. The company has a quick ratio of 3.81, a current ratio of 5.74 and a debt-to-equity ratio of 0.22.

Pro-Dex (NASDAQ:PDEX) last issued its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $0.27 EPS for the quarter. Pro-Dex had a return on equity of 22.60% and a net margin of 14.19%. The company had revenue of $7.24 million during the quarter.

Hedge funds have recently modified their holdings of the company. Squarepoint Ops LLC raised its stake in shares of Pro-Dex by 8.2% in the third quarter. Squarepoint Ops LLC now owns 18,500 shares of the medical instruments supplier’s stock valued at $283,000 after purchasing an additional 1,400 shares in the last quarter. Hancock Whitney Corp acquired a new position in shares of Pro-Dex in the third quarter valued at $161,000. Marshall Wace LLP acquired a new position in shares of Pro-Dex in the second quarter valued at $328,000. Vanguard Group Inc. raised its stake in shares of Pro-Dex by 23.3% in the second quarter. Vanguard Group Inc. now owns 83,355 shares of the medical instruments supplier’s stock valued at $1,082,000 after purchasing an additional 15,751 shares in the last quarter. Finally, BlackRock Inc. raised its stake in shares of Pro-Dex by 302.5% in the second quarter. BlackRock Inc. now owns 63,451 shares of the medical instruments supplier’s stock valued at $824,000 after purchasing an additional 47,685 shares in the last quarter. Institutional investors own 15.71% of the company’s stock.

Separately, ValuEngine upgraded Pro-Dex from a “sell” rating to a “hold” rating in a report on Monday, November 11th.

Pro-Dex Company Profile

Pro-Dex, Inc, together with its subsidiaries, designs, develops, and manufactures powered surgical instruments, dental instruments, and rotary air motors worldwide. It also manufactures plastic injection molds for various industries; and shavers and machined parts. In addition, it provides engineering, and quality and regulatory consulting services.

Featured Article: What is the QQQ ETF?

Receive News & Ratings for Pro-Dex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pro-Dex and related companies with MarketBeat.com's FREE daily email newsletter.